Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to WP1122 for the treatment of glioblastoma multiforme, according to a ...
January 21, 2009 — Glioblastoma multiforme has 4 distinct molecular subtypes, according to new data emerging from The Cancer Genome Atlas (TCGA) Research Network. The different subtypes show varying ...
Ottawa, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The global glioblastoma multiforme treatment market size is predicted to increase from USD 3.01 billion in 2025 to approximately USD 5.68 billion by 2033, ...
Glioblastoma multiforme is the most common malignant primary brain tumor in adults. Mean progression-free survival is just over 6 months; treatment with surgical resection, chemotherapy, and radiation ...
Glioblastoma multiforme (GBM) is the most common and aggressive type of tumor arising from star shaped cells called as astrocytes that make up supportive tissue of the brain. GBM has long baffled ...
Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM) ...
Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The global Glioblastoma Multiforme (GBM) ...
At Novocure, we are very proud of our ongoing commitment and dedication to improving the lives of people with brain cancer. Our patients, their families and caregivers are at the heart of everything ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results